3 Bargain Stocks Worth Buying at These 52-Week Lows

InvestorPlace2023-02-26

Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

623

Report

Comment（9）

hwhw123
·2023-02-27
K
Reply
Like
Report
Worpeng2002
·2023-02-27
Ok
Reply
Like
Report
andrew123
·2023-02-27
Like
Reply
1
Report
Seah CL
·2023-02-27
K
Reply
6
Report
LionKingAir
·2023-02-27
Ok
Reply
5
Report
NPC69
·2023-02-26
K
Reply
9
Report
Sanz13 8
·2023-02-26
Share your opinion about this news…
Reply
12
Report
lhkd
·2023-02-26
Cool
Reply
9
Report
Aidukas
·2023-02-26
Bubu
Reply
9
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2314104357?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-02-26 10:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2314104357","market":"us","top_or_hot":-1,"title":"3 Bargain Stocks Worth Buying at These 52-Week Lows","media":"InvestorPlace","content":"<div>\n<p>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out...</p>\n\n<a href=\"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/\">Source Link</a>\n\n</div>\n","source":"investorplace","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Bargain Stocks Worth Buying at These 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Bargain Stocks Worth Buying at These 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-26 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out...</p>\n\n<a href=\"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0689472784.USD","symbol_name":"安联收益及增长基金Cl AM AT Acc","start_time":0,"source_url":"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/","article_id":"2314104357","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2314104357","pubTimestamp":1677379035,"columns":[],"sourceInfo":{"source_id":"investorplace","name":"InvestorPlace"},"weMediaInfo":null,"summary":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Ph","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","BK4550":"红杉资本持仓","TQQQ":"纳指三倍做多ETF","BK4588":"碎股","STKH":"Steakholder Foods","TFFP":"TFF Pharmaceuticals","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","SQQQ":"纳指三倍做空ETF","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4155":"大卖场与超市","BK4581":"高盛持仓","BK4504":"桥水持仓","QQQ":"纳指100ETF","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","QLD":"纳指两倍做多ETF",".IXIC":"NASDAQ Composite","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU0079474960.USD":"联博美国增长基金A","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","QID":"纳指两倍做空ETF","COST":"好市多","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4212":"包装食品与肉类","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","PSQ":"纳指反向ETF","RGF":"The Real Good Food Company, Inc."},"translate_title":"3只值得在52周低点买入的廉价股票","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COST":1,"TFFP":1,"STKH":1,"RGF":1,".IXIC":0.76,"SQQQ":0.6,"QQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"TQQQ":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. Steakholder Foods (STKH): The company has multiple patents aimed at innovation and disruption in food. Real Good Food (RGF): Their line of healthy frozen food is competing in the right channels.Source: ShutterstockWho doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.TFFPTFF Pharmaceuticals$0.73STKHSteakholder Foods$0.80RGFReal Good Food$4.23TFF Pharmaceuticals (TFFP) Source: Hernan E. Schmidt / Shutterstock.comTFF Pharmaceuticals (NASDAQ:TFFP) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.Steakholder Foods (STKH) Source: barmalini/Shutterstock.comSteakholder Foods (NASDAQ:STKH) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.Real Good Food (RGF) Source: shutterstock.com/ampersandphotoThe last of our bargain stocks is another play on the future of food is The Real Good Food Company (NASDAQ:RGF). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as Costco (NASDAQ:COST) and Sam’s Club.The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9957401044,"gmtCreate":1677462895388,"gmtModify":1677463106385,"author":{"id":"3578710390898389","authorId":"3578710390898389","name":"hwhw123","avatar":"https://static.tigerbbs.com/d8403e7374bdcb179a82aff3b6d9338e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578710390898389","authorIdStr":"3578710390898389"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9957401044","repostId":2314104357,"repostType":4,"repost":{"id":"2314104357","kind":"highlight","pubTimestamp":1677379035,"share":"https://ttm.financial/m/news/2314104357?lang=&edition=fundamental","pubTime":"2023-02-26 10:37","market":"us","language":"en","title":"3 Bargain Stocks Worth Buying at These 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2314104357","media":"InvestorPlace","summary":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Ph","content":"<html><head></head><body><ul><li>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.</li><li><b><a href=\"https://laohu8.com/S/TFFP\">TFF Pharmaceuticals</a></b> (<b><u>TFFP</u></b>): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. </li><li><b><a href=\"https://laohu8.com/S/STKH\">Steakholder Foods</a></b> (<b><u>STKH</u></b>): The company has multiple patents aimed at innovation and disruption in food. </li><li><b>Real Good Food</b> (<b><u>RGF</u></b>): Their line of healthy frozen food is competing in the right channels.</li></ul><p><img src=\"https://investorplace.com/wp-content/uploads/2019/07/cheap-bargain-stock-tickers-768x432.jpg\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Shutterstock</p><p>Who doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.</p><p>But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.</p><p>In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.</p><p>While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.</p><p>With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.</p><table border=\"1\"><tbody><tr><td><b>TFFP</b></td><td>TFF Pharmaceuticals</td><td>$0.73</td></tr><tr><td><b>STKH</b></td><td>Steakholder Foods</td><td>$0.80</td></tr><tr><td><b>RGF</b></td><td>Real Good Food</td><td>$4.23</td></tr></tbody></table><h2></h2><h2>TFF Pharmaceuticals (TFFP) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Hernan E. Schmidt / Shutterstock.com</p><p><b>TFF Pharmaceuticals</b> (NASDAQ:<b>TFFP</b>) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”</p><p>Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.</p><p>And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.</p><p>One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.</p><p>Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.</p><h2></h2><h2>Steakholder Foods (STKH) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2020/12/fake_meat_1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: barmalini/Shutterstock.com</p><p><b>Steakholder Foods</b> (NASDAQ:<b>STKH</b>) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.</p><p>The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.</p><p>Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.</p><h2></h2><h2>Real Good Food (RGF) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2021/05/bakery-bread-1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: shutterstock.com/ampersandphoto</p><p>The last of our bargain stocks is another play on the future of food is <b>The Real Good Food Company</b> (NASDAQ:<b>RGF</b>). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as <b>Costco</b> (NASDAQ:<b>COST</b>) and Sam’s Club.</p><p>The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.</p><p>The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.</p><p>Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Bargain Stocks Worth Buying at These 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Bargain Stocks Worth Buying at These 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-26 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out...</p>\n\n<a href=\"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0079474960.USD":"联博美国增长基金A","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","RGF":"The Real Good Food Company, Inc.","QLD":"纳指两倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4550":"红杉资本持仓","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC",".IXIC":"NASDAQ Composite","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4155":"大卖场与超市","BK4581":"高盛持仓","BK4504":"桥水持仓","COST":"好市多","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4212":"包装食品与肉类","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","TQQQ":"纳指三倍做多ETF","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","TFFP":"TFF Pharmaceuticals","BK4585":"ETF&股票定投概念","STKH":"Steakholder Foods","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","QQQ":"纳指100ETF","BK4007":"制药","SQQQ":"纳指三倍做空ETF","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD"},"source_url":"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2314104357","content_text":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. Steakholder Foods (STKH): The company has multiple patents aimed at innovation and disruption in food. Real Good Food (RGF): Their line of healthy frozen food is competing in the right channels.Source: ShutterstockWho doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.TFFPTFF Pharmaceuticals$0.73STKHSteakholder Foods$0.80RGFReal Good Food$4.23TFF Pharmaceuticals (TFFP) Source: Hernan E. Schmidt / Shutterstock.comTFF Pharmaceuticals (NASDAQ:TFFP) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.Steakholder Foods (STKH) Source: barmalini/Shutterstock.comSteakholder Foods (NASDAQ:STKH) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.Real Good Food (RGF) Source: shutterstock.com/ampersandphotoThe last of our bargain stocks is another play on the future of food is The Real Good Food Company (NASDAQ:RGF). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as Costco (NASDAQ:COST) and Sam’s Club.The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9957578876,"gmtCreate":1677458641495,"gmtModify":1677458644804,"author":{"id":"3582000520700468","authorId":"3582000520700468","name":"Worpeng2002","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582000520700468","authorIdStr":"3582000520700468"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9957578876","repostId":2314104357,"repostType":4,"repost":{"id":"2314104357","kind":"highlight","pubTimestamp":1677379035,"share":"https://ttm.financial/m/news/2314104357?lang=&edition=fundamental","pubTime":"2023-02-26 10:37","market":"us","language":"en","title":"3 Bargain Stocks Worth Buying at These 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2314104357","media":"InvestorPlace","summary":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Ph","content":"<html><head></head><body><ul><li>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.</li><li><b><a href=\"https://laohu8.com/S/TFFP\">TFF Pharmaceuticals</a></b> (<b><u>TFFP</u></b>): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. </li><li><b><a href=\"https://laohu8.com/S/STKH\">Steakholder Foods</a></b> (<b><u>STKH</u></b>): The company has multiple patents aimed at innovation and disruption in food. </li><li><b>Real Good Food</b> (<b><u>RGF</u></b>): Their line of healthy frozen food is competing in the right channels.</li></ul><p><img src=\"https://investorplace.com/wp-content/uploads/2019/07/cheap-bargain-stock-tickers-768x432.jpg\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Shutterstock</p><p>Who doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.</p><p>But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.</p><p>In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.</p><p>While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.</p><p>With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.</p><table border=\"1\"><tbody><tr><td><b>TFFP</b></td><td>TFF Pharmaceuticals</td><td>$0.73</td></tr><tr><td><b>STKH</b></td><td>Steakholder Foods</td><td>$0.80</td></tr><tr><td><b>RGF</b></td><td>Real Good Food</td><td>$4.23</td></tr></tbody></table><h2></h2><h2>TFF Pharmaceuticals (TFFP) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Hernan E. Schmidt / Shutterstock.com</p><p><b>TFF Pharmaceuticals</b> (NASDAQ:<b>TFFP</b>) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”</p><p>Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.</p><p>And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.</p><p>One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.</p><p>Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.</p><h2></h2><h2>Steakholder Foods (STKH) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2020/12/fake_meat_1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: barmalini/Shutterstock.com</p><p><b>Steakholder Foods</b> (NASDAQ:<b>STKH</b>) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.</p><p>The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.</p><p>Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.</p><h2></h2><h2>Real Good Food (RGF) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2021/05/bakery-bread-1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: shutterstock.com/ampersandphoto</p><p>The last of our bargain stocks is another play on the future of food is <b>The Real Good Food Company</b> (NASDAQ:<b>RGF</b>). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as <b>Costco</b> (NASDAQ:<b>COST</b>) and Sam’s Club.</p><p>The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.</p><p>The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.</p><p>Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Bargain Stocks Worth Buying at These 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Bargain Stocks Worth Buying at These 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-26 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out...</p>\n\n<a href=\"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0079474960.USD":"联博美国增长基金A","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","RGF":"The Real Good Food Company, Inc.","QLD":"纳指两倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4550":"红杉资本持仓","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC",".IXIC":"NASDAQ Composite","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4155":"大卖场与超市","BK4581":"高盛持仓","BK4504":"桥水持仓","COST":"好市多","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4212":"包装食品与肉类","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","TQQQ":"纳指三倍做多ETF","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","TFFP":"TFF Pharmaceuticals","BK4585":"ETF&股票定投概念","STKH":"Steakholder Foods","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","QQQ":"纳指100ETF","BK4007":"制药","SQQQ":"纳指三倍做空ETF","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD"},"source_url":"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2314104357","content_text":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. Steakholder Foods (STKH): The company has multiple patents aimed at innovation and disruption in food. Real Good Food (RGF): Their line of healthy frozen food is competing in the right channels.Source: ShutterstockWho doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.TFFPTFF Pharmaceuticals$0.73STKHSteakholder Foods$0.80RGFReal Good Food$4.23TFF Pharmaceuticals (TFFP) Source: Hernan E. Schmidt / Shutterstock.comTFF Pharmaceuticals (NASDAQ:TFFP) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.Steakholder Foods (STKH) Source: barmalini/Shutterstock.comSteakholder Foods (NASDAQ:STKH) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.Real Good Food (RGF) Source: shutterstock.com/ampersandphotoThe last of our bargain stocks is another play on the future of food is The Real Good Food Company (NASDAQ:RGF). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as Costco (NASDAQ:COST) and Sam’s Club.The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9957541926,"gmtCreate":1677452645965,"gmtModify":1677452647776,"author":{"id":"3576260758860416","authorId":"3576260758860416","name":"andrew123","avatar":"https://community-static.tradeup.com/news/f2a1eaba26272212d42018e60e78b422","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":5,"crmLevelSwitch":0,"idStr":"3576260758860416","authorIdStr":"3576260758860416"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9957541926","repostId":2314104357,"repostType":4,"repost":{"id":"2314104357","kind":"highlight","pubTimestamp":1677379035,"share":"https://ttm.financial/m/news/2314104357?lang=&edition=fundamental","pubTime":"2023-02-26 10:37","market":"us","language":"en","title":"3 Bargain Stocks Worth Buying at These 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2314104357","media":"InvestorPlace","summary":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Ph","content":"<html><head></head><body><ul><li>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.</li><li><b><a href=\"https://laohu8.com/S/TFFP\">TFF Pharmaceuticals</a></b> (<b><u>TFFP</u></b>): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. </li><li><b><a href=\"https://laohu8.com/S/STKH\">Steakholder Foods</a></b> (<b><u>STKH</u></b>): The company has multiple patents aimed at innovation and disruption in food. </li><li><b>Real Good Food</b> (<b><u>RGF</u></b>): Their line of healthy frozen food is competing in the right channels.</li></ul><p><img src=\"https://investorplace.com/wp-content/uploads/2019/07/cheap-bargain-stock-tickers-768x432.jpg\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Shutterstock</p><p>Who doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.</p><p>But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.</p><p>In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.</p><p>While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.</p><p>With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.</p><table border=\"1\"><tbody><tr><td><b>TFFP</b></td><td>TFF Pharmaceuticals</td><td>$0.73</td></tr><tr><td><b>STKH</b></td><td>Steakholder Foods</td><td>$0.80</td></tr><tr><td><b>RGF</b></td><td>Real Good Food</td><td>$4.23</td></tr></tbody></table><h2></h2><h2>TFF Pharmaceuticals (TFFP) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Hernan E. Schmidt / Shutterstock.com</p><p><b>TFF Pharmaceuticals</b> (NASDAQ:<b>TFFP</b>) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”</p><p>Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.</p><p>And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.</p><p>One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.</p><p>Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.</p><h2></h2><h2>Steakholder Foods (STKH) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2020/12/fake_meat_1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: barmalini/Shutterstock.com</p><p><b>Steakholder Foods</b> (NASDAQ:<b>STKH</b>) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.</p><p>The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.</p><p>Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.</p><h2></h2><h2>Real Good Food (RGF) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2021/05/bakery-bread-1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: shutterstock.com/ampersandphoto</p><p>The last of our bargain stocks is another play on the future of food is <b>The Real Good Food Company</b> (NASDAQ:<b>RGF</b>). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as <b>Costco</b> (NASDAQ:<b>COST</b>) and Sam’s Club.</p><p>The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.</p><p>The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.</p><p>Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Bargain Stocks Worth Buying at These 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Bargain Stocks Worth Buying at These 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-26 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out...</p>\n\n<a href=\"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0079474960.USD":"联博美国增长基金A","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","RGF":"The Real Good Food Company, Inc.","QLD":"纳指两倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4550":"红杉资本持仓","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC",".IXIC":"NASDAQ Composite","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4155":"大卖场与超市","BK4581":"高盛持仓","BK4504":"桥水持仓","COST":"好市多","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4212":"包装食品与肉类","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","TQQQ":"纳指三倍做多ETF","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","TFFP":"TFF Pharmaceuticals","BK4585":"ETF&股票定投概念","STKH":"Steakholder Foods","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","QQQ":"纳指100ETF","BK4007":"制药","SQQQ":"纳指三倍做空ETF","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD"},"source_url":"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2314104357","content_text":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. Steakholder Foods (STKH): The company has multiple patents aimed at innovation and disruption in food. Real Good Food (RGF): Their line of healthy frozen food is competing in the right channels.Source: ShutterstockWho doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.TFFPTFF Pharmaceuticals$0.73STKHSteakholder Foods$0.80RGFReal Good Food$4.23TFF Pharmaceuticals (TFFP) Source: Hernan E. Schmidt / Shutterstock.comTFF Pharmaceuticals (NASDAQ:TFFP) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.Steakholder Foods (STKH) Source: barmalini/Shutterstock.comSteakholder Foods (NASDAQ:STKH) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.Real Good Food (RGF) Source: shutterstock.com/ampersandphotoThe last of our bargain stocks is another play on the future of food is The Real Good Food Company (NASDAQ:RGF). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as Costco (NASDAQ:COST) and Sam’s Club.The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9957556269,"gmtCreate":1677447134852,"gmtModify":1677447138213,"author":{"id":"4102135564535180","authorId":"4102135564535180","name":"Seah CL","avatar":"https://community-static.tradeup.com/news/970bca7b04e85a42a2c8eabed7ec96d0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4102135564535180","authorIdStr":"4102135564535180"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9957556269","repostId":2314104357,"repostType":4,"repost":{"id":"2314104357","kind":"highlight","pubTimestamp":1677379035,"share":"https://ttm.financial/m/news/2314104357?lang=&edition=fundamental","pubTime":"2023-02-26 10:37","market":"us","language":"en","title":"3 Bargain Stocks Worth Buying at These 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2314104357","media":"InvestorPlace","summary":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Ph","content":"<html><head></head><body><ul><li>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.</li><li><b><a href=\"https://laohu8.com/S/TFFP\">TFF Pharmaceuticals</a></b> (<b><u>TFFP</u></b>): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. </li><li><b><a href=\"https://laohu8.com/S/STKH\">Steakholder Foods</a></b> (<b><u>STKH</u></b>): The company has multiple patents aimed at innovation and disruption in food. </li><li><b>Real Good Food</b> (<b><u>RGF</u></b>): Their line of healthy frozen food is competing in the right channels.</li></ul><p><img src=\"https://investorplace.com/wp-content/uploads/2019/07/cheap-bargain-stock-tickers-768x432.jpg\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Shutterstock</p><p>Who doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.</p><p>But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.</p><p>In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.</p><p>While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.</p><p>With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.</p><table border=\"1\"><tbody><tr><td><b>TFFP</b></td><td>TFF Pharmaceuticals</td><td>$0.73</td></tr><tr><td><b>STKH</b></td><td>Steakholder Foods</td><td>$0.80</td></tr><tr><td><b>RGF</b></td><td>Real Good Food</td><td>$4.23</td></tr></tbody></table><h2></h2><h2>TFF Pharmaceuticals (TFFP) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Hernan E. Schmidt / Shutterstock.com</p><p><b>TFF Pharmaceuticals</b> (NASDAQ:<b>TFFP</b>) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”</p><p>Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.</p><p>And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.</p><p>One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.</p><p>Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.</p><h2></h2><h2>Steakholder Foods (STKH) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2020/12/fake_meat_1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: barmalini/Shutterstock.com</p><p><b>Steakholder Foods</b> (NASDAQ:<b>STKH</b>) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.</p><p>The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.</p><p>Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.</p><h2></h2><h2>Real Good Food (RGF) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2021/05/bakery-bread-1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: shutterstock.com/ampersandphoto</p><p>The last of our bargain stocks is another play on the future of food is <b>The Real Good Food Company</b> (NASDAQ:<b>RGF</b>). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as <b>Costco</b> (NASDAQ:<b>COST</b>) and Sam’s Club.</p><p>The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.</p><p>The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.</p><p>Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Bargain Stocks Worth Buying at These 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Bargain Stocks Worth Buying at These 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-26 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out...</p>\n\n<a href=\"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0079474960.USD":"联博美国增长基金A","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","RGF":"The Real Good Food Company, Inc.","QLD":"纳指两倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4550":"红杉资本持仓","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC",".IXIC":"NASDAQ Composite","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4155":"大卖场与超市","BK4581":"高盛持仓","BK4504":"桥水持仓","COST":"好市多","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4212":"包装食品与肉类","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","TQQQ":"纳指三倍做多ETF","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","TFFP":"TFF Pharmaceuticals","BK4585":"ETF&股票定投概念","STKH":"Steakholder Foods","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","QQQ":"纳指100ETF","BK4007":"制药","SQQQ":"纳指三倍做空ETF","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD"},"source_url":"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2314104357","content_text":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. Steakholder Foods (STKH): The company has multiple patents aimed at innovation and disruption in food. Real Good Food (RGF): Their line of healthy frozen food is competing in the right channels.Source: ShutterstockWho doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.TFFPTFF Pharmaceuticals$0.73STKHSteakholder Foods$0.80RGFReal Good Food$4.23TFF Pharmaceuticals (TFFP) Source: Hernan E. Schmidt / Shutterstock.comTFF Pharmaceuticals (NASDAQ:TFFP) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.Steakholder Foods (STKH) Source: barmalini/Shutterstock.comSteakholder Foods (NASDAQ:STKH) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.Real Good Food (RGF) Source: shutterstock.com/ampersandphotoThe last of our bargain stocks is another play on the future of food is The Real Good Food Company (NASDAQ:RGF). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as Costco (NASDAQ:COST) and Sam’s Club.The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9957550841,"gmtCreate":1677427584084,"gmtModify":1677427587920,"author":{"id":"3582891836402828","authorId":"3582891836402828","name":"LionKingAir","avatar":"https://static.tigerbbs.com/94f60573baa578de19304c643193dad9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582891836402828","authorIdStr":"3582891836402828"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9957550841","repostId":2314104357,"repostType":4,"repost":{"id":"2314104357","kind":"highlight","pubTimestamp":1677379035,"share":"https://ttm.financial/m/news/2314104357?lang=&edition=fundamental","pubTime":"2023-02-26 10:37","market":"us","language":"en","title":"3 Bargain Stocks Worth Buying at These 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2314104357","media":"InvestorPlace","summary":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Ph","content":"<html><head></head><body><ul><li>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.</li><li><b><a href=\"https://laohu8.com/S/TFFP\">TFF Pharmaceuticals</a></b> (<b><u>TFFP</u></b>): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. </li><li><b><a href=\"https://laohu8.com/S/STKH\">Steakholder Foods</a></b> (<b><u>STKH</u></b>): The company has multiple patents aimed at innovation and disruption in food. </li><li><b>Real Good Food</b> (<b><u>RGF</u></b>): Their line of healthy frozen food is competing in the right channels.</li></ul><p><img src=\"https://investorplace.com/wp-content/uploads/2019/07/cheap-bargain-stock-tickers-768x432.jpg\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Shutterstock</p><p>Who doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.</p><p>But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.</p><p>In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.</p><p>While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.</p><p>With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.</p><table border=\"1\"><tbody><tr><td><b>TFFP</b></td><td>TFF Pharmaceuticals</td><td>$0.73</td></tr><tr><td><b>STKH</b></td><td>Steakholder Foods</td><td>$0.80</td></tr><tr><td><b>RGF</b></td><td>Real Good Food</td><td>$4.23</td></tr></tbody></table><h2></h2><h2>TFF Pharmaceuticals (TFFP) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Hernan E. Schmidt / Shutterstock.com</p><p><b>TFF Pharmaceuticals</b> (NASDAQ:<b>TFFP</b>) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”</p><p>Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.</p><p>And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.</p><p>One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.</p><p>Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.</p><h2></h2><h2>Steakholder Foods (STKH) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2020/12/fake_meat_1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: barmalini/Shutterstock.com</p><p><b>Steakholder Foods</b> (NASDAQ:<b>STKH</b>) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.</p><p>The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.</p><p>Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.</p><h2></h2><h2>Real Good Food (RGF) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2021/05/bakery-bread-1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: shutterstock.com/ampersandphoto</p><p>The last of our bargain stocks is another play on the future of food is <b>The Real Good Food Company</b> (NASDAQ:<b>RGF</b>). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as <b>Costco</b> (NASDAQ:<b>COST</b>) and Sam’s Club.</p><p>The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.</p><p>The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.</p><p>Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Bargain Stocks Worth Buying at These 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Bargain Stocks Worth Buying at These 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-26 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out...</p>\n\n<a href=\"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0079474960.USD":"联博美国增长基金A","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","RGF":"The Real Good Food Company, Inc.","QLD":"纳指两倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4550":"红杉资本持仓","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC",".IXIC":"NASDAQ Composite","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4155":"大卖场与超市","BK4581":"高盛持仓","BK4504":"桥水持仓","COST":"好市多","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4212":"包装食品与肉类","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","TQQQ":"纳指三倍做多ETF","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","TFFP":"TFF Pharmaceuticals","BK4585":"ETF&股票定投概念","STKH":"Steakholder Foods","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","QQQ":"纳指100ETF","BK4007":"制药","SQQQ":"纳指三倍做空ETF","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD"},"source_url":"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2314104357","content_text":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. Steakholder Foods (STKH): The company has multiple patents aimed at innovation and disruption in food. Real Good Food (RGF): Their line of healthy frozen food is competing in the right channels.Source: ShutterstockWho doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.TFFPTFF Pharmaceuticals$0.73STKHSteakholder Foods$0.80RGFReal Good Food$4.23TFF Pharmaceuticals (TFFP) Source: Hernan E. Schmidt / Shutterstock.comTFF Pharmaceuticals (NASDAQ:TFFP) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.Steakholder Foods (STKH) Source: barmalini/Shutterstock.comSteakholder Foods (NASDAQ:STKH) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.Real Good Food (RGF) Source: shutterstock.com/ampersandphotoThe last of our bargain stocks is another play on the future of food is The Real Good Food Company (NASDAQ:RGF). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as Costco (NASDAQ:COST) and Sam’s Club.The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9957523273,"gmtCreate":1677419595992,"gmtModify":1677419599530,"author":{"id":"3584779133668268","authorId":"3584779133668268","name":"NPC69","avatar":"https://static.tigerbbs.com/47e7ac55312ae8dd1c9e7cb92adad089","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3584779133668268","authorIdStr":"3584779133668268"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9957523273","repostId":2314104357,"repostType":4,"repost":{"id":"2314104357","kind":"highlight","pubTimestamp":1677379035,"share":"https://ttm.financial/m/news/2314104357?lang=&edition=fundamental","pubTime":"2023-02-26 10:37","market":"us","language":"en","title":"3 Bargain Stocks Worth Buying at These 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2314104357","media":"InvestorPlace","summary":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Ph","content":"<html><head></head><body><ul><li>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.</li><li><b><a href=\"https://laohu8.com/S/TFFP\">TFF Pharmaceuticals</a></b> (<b><u>TFFP</u></b>): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. </li><li><b><a href=\"https://laohu8.com/S/STKH\">Steakholder Foods</a></b> (<b><u>STKH</u></b>): The company has multiple patents aimed at innovation and disruption in food. </li><li><b>Real Good Food</b> (<b><u>RGF</u></b>): Their line of healthy frozen food is competing in the right channels.</li></ul><p><img src=\"https://investorplace.com/wp-content/uploads/2019/07/cheap-bargain-stock-tickers-768x432.jpg\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Shutterstock</p><p>Who doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.</p><p>But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.</p><p>In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.</p><p>While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.</p><p>With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.</p><table border=\"1\"><tbody><tr><td><b>TFFP</b></td><td>TFF Pharmaceuticals</td><td>$0.73</td></tr><tr><td><b>STKH</b></td><td>Steakholder Foods</td><td>$0.80</td></tr><tr><td><b>RGF</b></td><td>Real Good Food</td><td>$4.23</td></tr></tbody></table><h2></h2><h2>TFF Pharmaceuticals (TFFP) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Hernan E. Schmidt / Shutterstock.com</p><p><b>TFF Pharmaceuticals</b> (NASDAQ:<b>TFFP</b>) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”</p><p>Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.</p><p>And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.</p><p>One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.</p><p>Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.</p><h2></h2><h2>Steakholder Foods (STKH) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2020/12/fake_meat_1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: barmalini/Shutterstock.com</p><p><b>Steakholder Foods</b> (NASDAQ:<b>STKH</b>) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.</p><p>The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.</p><p>Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.</p><h2></h2><h2>Real Good Food (RGF) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2021/05/bakery-bread-1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: shutterstock.com/ampersandphoto</p><p>The last of our bargain stocks is another play on the future of food is <b>The Real Good Food Company</b> (NASDAQ:<b>RGF</b>). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as <b>Costco</b> (NASDAQ:<b>COST</b>) and Sam’s Club.</p><p>The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.</p><p>The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.</p><p>Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Bargain Stocks Worth Buying at These 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Bargain Stocks Worth Buying at These 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-26 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out...</p>\n\n<a href=\"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0079474960.USD":"联博美国增长基金A","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","RGF":"The Real Good Food Company, Inc.","QLD":"纳指两倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4550":"红杉资本持仓","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC",".IXIC":"NASDAQ Composite","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4155":"大卖场与超市","BK4581":"高盛持仓","BK4504":"桥水持仓","COST":"好市多","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4212":"包装食品与肉类","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","TQQQ":"纳指三倍做多ETF","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","TFFP":"TFF Pharmaceuticals","BK4585":"ETF&股票定投概念","STKH":"Steakholder Foods","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","QQQ":"纳指100ETF","BK4007":"制药","SQQQ":"纳指三倍做空ETF","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD"},"source_url":"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2314104357","content_text":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. Steakholder Foods (STKH): The company has multiple patents aimed at innovation and disruption in food. Real Good Food (RGF): Their line of healthy frozen food is competing in the right channels.Source: ShutterstockWho doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.TFFPTFF Pharmaceuticals$0.73STKHSteakholder Foods$0.80RGFReal Good Food$4.23TFF Pharmaceuticals (TFFP) Source: Hernan E. Schmidt / Shutterstock.comTFF Pharmaceuticals (NASDAQ:TFFP) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.Steakholder Foods (STKH) Source: barmalini/Shutterstock.comSteakholder Foods (NASDAQ:STKH) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.Real Good Food (RGF) Source: shutterstock.com/ampersandphotoThe last of our bargain stocks is another play on the future of food is The Real Good Food Company (NASDAQ:RGF). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as Costco (NASDAQ:COST) and Sam’s Club.The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9957561112,"gmtCreate":1677406037237,"gmtModify":1677407337356,"author":{"id":"4128031068075382","authorId":"4128031068075382","name":"Sanz13 8","avatar":"https://community-static.tradeup.com/news/2d76b14dbabd0a8eab48c97801bef4a7","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4128031068075382","authorIdStr":"4128031068075382"},"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9957561112","repostId":2314104357,"repostType":2,"repost":{"id":"2314104357","kind":"highlight","pubTimestamp":1677379035,"share":"https://ttm.financial/m/news/2314104357?lang=&edition=fundamental","pubTime":"2023-02-26 10:37","market":"us","language":"en","title":"3 Bargain Stocks Worth Buying at These 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2314104357","media":"InvestorPlace","summary":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Ph","content":"<html><head></head><body><ul><li>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.</li><li><b><a href=\"https://laohu8.com/S/TFFP\">TFF Pharmaceuticals</a></b> (<b><u>TFFP</u></b>): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. </li><li><b><a href=\"https://laohu8.com/S/STKH\">Steakholder Foods</a></b> (<b><u>STKH</u></b>): The company has multiple patents aimed at innovation and disruption in food. </li><li><b>Real Good Food</b> (<b><u>RGF</u></b>): Their line of healthy frozen food is competing in the right channels.</li></ul><p><img src=\"https://investorplace.com/wp-content/uploads/2019/07/cheap-bargain-stock-tickers-768x432.jpg\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Shutterstock</p><p>Who doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.</p><p>But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.</p><p>In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.</p><p>While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.</p><p>With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.</p><table border=\"1\"><tbody><tr><td><b>TFFP</b></td><td>TFF Pharmaceuticals</td><td>$0.73</td></tr><tr><td><b>STKH</b></td><td>Steakholder Foods</td><td>$0.80</td></tr><tr><td><b>RGF</b></td><td>Real Good Food</td><td>$4.23</td></tr></tbody></table><h2></h2><h2>TFF Pharmaceuticals (TFFP) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Hernan E. Schmidt / Shutterstock.com</p><p><b>TFF Pharmaceuticals</b> (NASDAQ:<b>TFFP</b>) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”</p><p>Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.</p><p>And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.</p><p>One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.</p><p>Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.</p><h2></h2><h2>Steakholder Foods (STKH) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2020/12/fake_meat_1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: barmalini/Shutterstock.com</p><p><b>Steakholder Foods</b> (NASDAQ:<b>STKH</b>) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.</p><p>The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.</p><p>Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.</p><h2></h2><h2>Real Good Food (RGF) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2021/05/bakery-bread-1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: shutterstock.com/ampersandphoto</p><p>The last of our bargain stocks is another play on the future of food is <b>The Real Good Food Company</b> (NASDAQ:<b>RGF</b>). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as <b>Costco</b> (NASDAQ:<b>COST</b>) and Sam’s Club.</p><p>The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.</p><p>The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.</p><p>Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Bargain Stocks Worth Buying at These 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Bargain Stocks Worth Buying at These 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-26 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out...</p>\n\n<a href=\"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0079474960.USD":"联博美国增长基金A","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","RGF":"The Real Good Food Company, Inc.","QLD":"纳指两倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4550":"红杉资本持仓","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC",".IXIC":"NASDAQ Composite","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4155":"大卖场与超市","BK4581":"高盛持仓","BK4504":"桥水持仓","COST":"好市多","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4212":"包装食品与肉类","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","TQQQ":"纳指三倍做多ETF","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","TFFP":"TFF Pharmaceuticals","BK4585":"ETF&股票定投概念","STKH":"Steakholder Foods","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","QQQ":"纳指100ETF","BK4007":"制药","SQQQ":"纳指三倍做空ETF","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD"},"source_url":"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2314104357","content_text":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. Steakholder Foods (STKH): The company has multiple patents aimed at innovation and disruption in food. Real Good Food (RGF): Their line of healthy frozen food is competing in the right channels.Source: ShutterstockWho doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.TFFPTFF Pharmaceuticals$0.73STKHSteakholder Foods$0.80RGFReal Good Food$4.23TFF Pharmaceuticals (TFFP) Source: Hernan E. Schmidt / Shutterstock.comTFF Pharmaceuticals (NASDAQ:TFFP) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.Steakholder Foods (STKH) Source: barmalini/Shutterstock.comSteakholder Foods (NASDAQ:STKH) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.Real Good Food (RGF) Source: shutterstock.com/ampersandphotoThe last of our bargain stocks is another play on the future of food is The Real Good Food Company (NASDAQ:RGF). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as Costco (NASDAQ:COST) and Sam’s Club.The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9957581251,"gmtCreate":1677394872273,"gmtModify":1677394875927,"author":{"id":"4093679892947360","authorId":"4093679892947360","name":"lhkd","avatar":"https://static.tigerbbs.com/ea8473a1d30ab714b1790f12dc7e7746","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4093679892947360","authorIdStr":"4093679892947360"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9957581251","repostId":2314104357,"repostType":4,"repost":{"id":"2314104357","kind":"highlight","pubTimestamp":1677379035,"share":"https://ttm.financial/m/news/2314104357?lang=&edition=fundamental","pubTime":"2023-02-26 10:37","market":"us","language":"en","title":"3 Bargain Stocks Worth Buying at These 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2314104357","media":"InvestorPlace","summary":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Ph","content":"<html><head></head><body><ul><li>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.</li><li><b><a href=\"https://laohu8.com/S/TFFP\">TFF Pharmaceuticals</a></b> (<b><u>TFFP</u></b>): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. </li><li><b><a href=\"https://laohu8.com/S/STKH\">Steakholder Foods</a></b> (<b><u>STKH</u></b>): The company has multiple patents aimed at innovation and disruption in food. </li><li><b>Real Good Food</b> (<b><u>RGF</u></b>): Their line of healthy frozen food is competing in the right channels.</li></ul><p><img src=\"https://investorplace.com/wp-content/uploads/2019/07/cheap-bargain-stock-tickers-768x432.jpg\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Shutterstock</p><p>Who doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.</p><p>But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.</p><p>In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.</p><p>While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.</p><p>With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.</p><table border=\"1\"><tbody><tr><td><b>TFFP</b></td><td>TFF Pharmaceuticals</td><td>$0.73</td></tr><tr><td><b>STKH</b></td><td>Steakholder Foods</td><td>$0.80</td></tr><tr><td><b>RGF</b></td><td>Real Good Food</td><td>$4.23</td></tr></tbody></table><h2></h2><h2>TFF Pharmaceuticals (TFFP) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Hernan E. Schmidt / Shutterstock.com</p><p><b>TFF Pharmaceuticals</b> (NASDAQ:<b>TFFP</b>) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”</p><p>Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.</p><p>And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.</p><p>One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.</p><p>Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.</p><h2></h2><h2>Steakholder Foods (STKH) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2020/12/fake_meat_1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: barmalini/Shutterstock.com</p><p><b>Steakholder Foods</b> (NASDAQ:<b>STKH</b>) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.</p><p>The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.</p><p>Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.</p><h2></h2><h2>Real Good Food (RGF) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2021/05/bakery-bread-1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: shutterstock.com/ampersandphoto</p><p>The last of our bargain stocks is another play on the future of food is <b>The Real Good Food Company</b> (NASDAQ:<b>RGF</b>). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as <b>Costco</b> (NASDAQ:<b>COST</b>) and Sam’s Club.</p><p>The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.</p><p>The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.</p><p>Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Bargain Stocks Worth Buying at These 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Bargain Stocks Worth Buying at These 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-26 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out...</p>\n\n<a href=\"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0079474960.USD":"联博美国增长基金A","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","RGF":"The Real Good Food Company, Inc.","QLD":"纳指两倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4550":"红杉资本持仓","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC",".IXIC":"NASDAQ Composite","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4155":"大卖场与超市","BK4581":"高盛持仓","BK4504":"桥水持仓","COST":"好市多","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4212":"包装食品与肉类","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","TQQQ":"纳指三倍做多ETF","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","TFFP":"TFF Pharmaceuticals","BK4585":"ETF&股票定投概念","STKH":"Steakholder Foods","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","QQQ":"纳指100ETF","BK4007":"制药","SQQQ":"纳指三倍做空ETF","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD"},"source_url":"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2314104357","content_text":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. Steakholder Foods (STKH): The company has multiple patents aimed at innovation and disruption in food. Real Good Food (RGF): Their line of healthy frozen food is competing in the right channels.Source: ShutterstockWho doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.TFFPTFF Pharmaceuticals$0.73STKHSteakholder Foods$0.80RGFReal Good Food$4.23TFF Pharmaceuticals (TFFP) Source: Hernan E. Schmidt / Shutterstock.comTFF Pharmaceuticals (NASDAQ:TFFP) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.Steakholder Foods (STKH) Source: barmalini/Shutterstock.comSteakholder Foods (NASDAQ:STKH) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.Real Good Food (RGF) Source: shutterstock.com/ampersandphotoThe last of our bargain stocks is another play on the future of food is The Real Good Food Company (NASDAQ:RGF). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as Costco (NASDAQ:COST) and Sam’s Club.The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9957583537,"gmtCreate":1677393890630,"gmtModify":1677393894392,"author":{"id":"4133623950260892","authorId":"4133623950260892","name":"Aidukas","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":1,"idStr":"4133623950260892","authorIdStr":"4133623950260892"},"htmlText":"Bubu","listText":"Bubu","text":"Bubu","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9957583537","repostId":2314104357,"repostType":4,"repost":{"id":"2314104357","kind":"highlight","pubTimestamp":1677379035,"share":"https://ttm.financial/m/news/2314104357?lang=&edition=fundamental","pubTime":"2023-02-26 10:37","market":"us","language":"en","title":"3 Bargain Stocks Worth Buying at These 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2314104357","media":"InvestorPlace","summary":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Ph","content":"<html><head></head><body><ul><li>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.</li><li><b><a href=\"https://laohu8.com/S/TFFP\">TFF Pharmaceuticals</a></b> (<b><u>TFFP</u></b>): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. </li><li><b><a href=\"https://laohu8.com/S/STKH\">Steakholder Foods</a></b> (<b><u>STKH</u></b>): The company has multiple patents aimed at innovation and disruption in food. </li><li><b>Real Good Food</b> (<b><u>RGF</u></b>): Their line of healthy frozen food is competing in the right channels.</li></ul><p><img src=\"https://investorplace.com/wp-content/uploads/2019/07/cheap-bargain-stock-tickers-768x432.jpg\" tg-width=\"768\" tg-height=\"432\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Shutterstock</p><p>Who doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.</p><p>But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.</p><p>In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.</p><p>While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.</p><p>With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.</p><table border=\"1\"><tbody><tr><td><b>TFFP</b></td><td>TFF Pharmaceuticals</td><td>$0.73</td></tr><tr><td><b>STKH</b></td><td>Steakholder Foods</td><td>$0.80</td></tr><tr><td><b>RGF</b></td><td>Real Good Food</td><td>$4.23</td></tr></tbody></table><h2></h2><h2>TFF Pharmaceuticals (TFFP) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: Hernan E. Schmidt / Shutterstock.com</p><p><b>TFF Pharmaceuticals</b> (NASDAQ:<b>TFFP</b>) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”</p><p>Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.</p><p>And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.</p><p>One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.</p><p>Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.</p><h2></h2><h2>Steakholder Foods (STKH) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2020/12/fake_meat_1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: barmalini/Shutterstock.com</p><p><b>Steakholder Foods</b> (NASDAQ:<b>STKH</b>) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.</p><p>The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.</p><p>Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.</p><h2></h2><h2>Real Good Food (RGF) </h2><p><img src=\"https://investorplace.com/wp-content/uploads/2021/05/bakery-bread-1600-300x169.jpg\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Source: shutterstock.com/ampersandphoto</p><p>The last of our bargain stocks is another play on the future of food is <b>The Real Good Food Company</b> (NASDAQ:<b>RGF</b>). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as <b>Costco</b> (NASDAQ:<b>COST</b>) and Sam’s Club.</p><p>The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.</p><p>The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.</p><p>Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Bargain Stocks Worth Buying at These 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Bargain Stocks Worth Buying at These 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-26 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out...</p>\n\n<a href=\"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0079474960.USD":"联博美国增长基金A","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","RGF":"The Real Good Food Company, Inc.","QLD":"纳指两倍做多ETF","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4550":"红杉资本持仓","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC",".IXIC":"NASDAQ Composite","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4155":"大卖场与超市","BK4581":"高盛持仓","BK4504":"桥水持仓","COST":"好市多","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","QID":"纳指两倍做空ETF","PSQ":"纳指反向ETF","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4212":"包装食品与肉类","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","TQQQ":"纳指三倍做多ETF","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","TFFP":"TFF Pharmaceuticals","BK4585":"ETF&股票定投概念","STKH":"Steakholder Foods","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","QQQ":"纳指100ETF","BK4007":"制药","SQQQ":"纳指三倍做空ETF","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD"},"source_url":"https://investorplace.com/2023/02/3-bargain-stocks-worth-buying-at-these-52-week-lows/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2314104357","content_text":"Finding stocks trading at 52-week lows can be a profitable strategy for risk-tolerant traders.TFF Pharmaceuticals (TFFP): If this clinical-stage biopharma company can find a partner before it runs out of cash, its runway could be long. Steakholder Foods (STKH): The company has multiple patents aimed at innovation and disruption in food. Real Good Food (RGF): Their line of healthy frozen food is competing in the right channels.Source: ShutterstockWho doesn’t love a bargain? We look for deals in many places. And when it comes to investing, we look for bargain stocks. This can mean different things to different investors. Some investors will consider a stock a bargain if it’s undervalued.But this is no ordinary market. You’ve heard of hard landings and soft landings. But right now, there are growing concerns about stagflation which is the scenario of no immediate landing. That would be bad news for even the “safest” of stocks. That’s why it may be time to try something new.In coming up with the stocks for this article, I’m looking at stocks that are trading at or near 52-week lows and have some analyst support.While no strategy is foolproof, finding stocks trading at 52-week lows in a market like this can make for a profitable trade. If nothing else, these bargain stocks aren’t overvalued. And if they have the support of an analyst or a handful of analysts, it can signal that the 52-week low will serve as support.With that in mind, every stock on this list is a penny stock. Penny stocks carry a tremendous risk and the possibility of an outsized reward. And while each stock has a story that could send it much higher, each of these bargain stocks may never deliver on its promise.TFFPTFF Pharmaceuticals$0.73STKHSteakholder Foods$0.80RGFReal Good Food$4.23TFF Pharmaceuticals (TFFP) Source: Hernan E. Schmidt / Shutterstock.comTFF Pharmaceuticals (NASDAQ:TFFP) is a clinical-stage biopharmaceutical company that has developed its proprietary Thin Film Freezing technology. The technology attempts to “transform medicines into elegant and potent dry powders for better efficacy, safety, and stability.”Although the company does not have a product through clinical trials, there’s no evidence that the technology doesn’t work. But to date, the company has not found a partner that would provide the necessary funding.And, like all biotechs, that’s the real issue. The company said in December that it was capitalized through 2023. But they won’t have a product through clinical trials until 2024. So that could mean another round of share dilution unless they find a partner.One thing that may help that process is that the company has appointed an interim CEO. The leadership of former CEO Glenn Mattes was called into question by shareholders.Analysts do not widely cover the company. But it does have the support of the analysts that do cover the stock. It has a consensus buy rating and a price target of $20, a gain of over 2,900%.Steakholder Foods (STKH) Source: barmalini/Shutterstock.comSteakholder Foods (NASDAQ:STKH) was formerly known as MeaTech 3D. The new name, however, fits into their mission of being a leader in the emerging field of structured or cultivated meat. And the play on the word “stakeholder” can’t hurt when you’re a company bound to be looked upon favorably by investors who prioritize ESG (environmental, sustainability, and corporate governance) standards.The company is using 3D bioprinting to make meat from animal cells. The goal is to feed a growing population while protecting the environment and the welfare of animals. The company has applied for 18 patents and has received and been granted four.Numerous analysts suggest cultivated meat will have a large addressable market between now and 2050. That makes STKH stock a long-term play. However, as the company’s recent $6.5 million securities offering reminds investors, this will still be volatile.Real Good Food (RGF) Source: shutterstock.com/ampersandphotoThe last of our bargain stocks is another play on the future of food is The Real Good Food Company (NASDAQ:RGF). But this company is generating revenue today. And the company’s gluten-free and grain-free products are in several notable channels, such as Costco (NASDAQ:COST) and Sam’s Club.The marketing message is that the company offers products that have more protein with fewer carbs and without sacrificing taste.The company was profitable GAAP-based in two out of the last three quarters. But the company went from a GAAP profit of 49 cents a share to a loss of 51 cents a share in the previous quarter. And with revenue jumping over 20% sequentially, the company may have difficulty passing inflation-related costs along to its customers.Revenue and earnings are expected to grow at 38% and 34% in the next five years. Eight analysts give RGF stock a $14.28 mean price target. That’s a gain of over 230% from its current price.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":623,"commentSize":9,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}